First Person With Cystic Fibrosis Dosed In Phase 1 Trial Of Investigational Therapy Cm001, Designed To Form Ion Channels To Help Restore Airway Function

CHAMPAIGN, Ill., Oct. 30, 2023. cystetic Medicines, Inc., a clinical-stage biotechnology company developing small molecule channels that serve as molecular prosthetics for missing or dysfunctional CFTR protein channels, announced today it has dosed...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials